Edenred: Disclosure of Share Capital and Voting Rights as of october 31, 2022 Read more about Edenred: Disclosure of Share Capital and Voting Rights as of october 31, 2022
ABEO: H1 2022/23 revenue up 23.2% to EUR 117.8m - Solid H1 order intake of EUR 113.8m Read more about ABEO: H1 2022/23 revenue up 23.2% to EUR 117.8m - Solid H1 order intake of EUR 113.8m
Valbiotis Announces the Availability of an Amendment to the Universal Registration Document Read more about Valbiotis Announces the Availability of an Amendment to the Universal Registration Document
THIRD-QUARTER 2022 TURNOVER: EUR 586.6 MILLION Read more about THIRD-QUARTER 2022 TURNOVER: EUR 586.6 MILLION
APPOINTMENT OF OLIVIER CARTON AS CHIEF FINANCIAL OFFICER Read more about APPOINTMENT OF OLIVIER CARTON AS CHIEF FINANCIAL OFFICER
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022 Read more about MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs Read more about OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs
NAV down 1.1% in the third quarter. Further diversification with a second co-investment alongside HG Capital Read more about NAV down 1.1% in the third quarter. Further diversification with a second co-investment alongside HG Capital